Resumen de: US2025195447A1
A novel biomimetic nano-sphere M@P-WI includes PLGA nanoparticles and the membrane of breast cancer EO771 cells. The PLGA nanoparticles are encapsulated within the membrane of breast cancer EO771 cells, and IR780 and DDR2 inhibitor WRG-28 are embedded in the PLGA nanoparticles. A method for preparing and applying the novel biomimetic nano-sphere M@P-WI is also provided. The method utilizes the aforementioned novel biomimetic nano-sphere M@P-WI, to trigger the conversion of light into heat energy upon near-infrared laser irradiation. This “burns” the tumor and induces specific immune responses within the body, inhibiting tumor recurrence and metastasis. Under the action of WRG-28, it promotes apoptosis of cancer-associated fibroblasts (CAF), reduces the remodeling of tumor extracellular matrix microenvironment, enhances the distribution of nanomaterials within the tumor, and restricts the invasiveness of breast cancer cells. With laser irradiation, the photosensitizer exhibits its maximum efficacy, achieving complete elimination of TNBC rich in extracellular matrix.
Resumen de: CN120346183A
本发明涉及一种包载卡介苗裂解物的过表达PD‑1的细胞外囊泡及其制备方法和应用,本发明的方法包括以下步骤:1、对肿瘤细胞的转染和筛选构建PD‑1过表达肿瘤细胞系LLC/PD‑1;2、梯度离心法得到过表达PD‑1肿瘤细胞外囊泡LPV;3、卡介苗热灭活法制备卡介苗裂解物BL;4、将过表达PD‑1的肿瘤源性细胞外囊泡(TEVs)与卡介苗裂解物BL挤压制备载药囊泡LP@BLV。本发明将工程化过表达PD‑1的肿瘤细胞外囊泡包载卡介苗裂解物制备成新型载药囊泡,兼具直接杀伤肿瘤细胞和激活抗肿瘤免疫应答双重功能,同时具有较高的生物安全性。
Resumen de: AU2023385485A1
The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various disorders.
Resumen de: MX2025002504A
Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.
Resumen de: WO2024052698A1
The present invention relates to compositions, in particular to lipid-based compositions that solubilise and/or encapsulate (sometimes high concentrations of) copper complex(es) (and/or derivatives or analogues thereof). Such lipid-based compositions offer a variety of uses, including in their capacity as topical or ingestible formulations. Such compositions permit delivery of high concentrations of copper complex(es) (and derivatives) in a highly bioavailable form.
Resumen de: TW202432138A
The present invention relates to a novel ionizable lipid compound represented by formula (I) or a salt thereof, and lipid nanoparticles including the same. Lipid nanoparticles including a novel ionizable lipid compound according to the present invention have excellent nucleic acid encapsulation efficiency and high cell delivery efficiency of nucleic acids.
Resumen de: WO2024125469A1
Disclosed herein are novel compounds and compositions involving the same, lipid particles including the novel compounds, as well as additional lipids such as phospholipids, structural lipids, and PEG lipids, and the use of the compounds or the lipid particles in the delivery of a therapeutic agent to a subject, targeted organs, or targeted cells.
Resumen de: WO2024102434A1
Disclosed herein are RNA compositions including one or more polynucleotides encoding one or more gene editing systems, formulated within a lipid reconstructed natural messenger pack (LNMP) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making an RNA composition, comprising reconstituting a film comprising purified NMP lipids in the presence of an ionizable lipid to produce a LNMP comprising the ionizable lipid, and loading into the LNMPs with one or more polynucleotides encoding one or more gene editing systems. The disclosure also includes an RNA composition that is repeat dosable.
Resumen de: AU2023307461A1
The present invention relates to a high-Z element containing nanoparticles for use in a method of treating a tumor by radiopharmaceutical therapy, in a subject in need thereof, the method comprising a combined administration of an efficient amount of said high-Z element containing nanoparticles and of an efficient amount of a radionuclide containing therapeutic radiopharmaceutical, wherein the high-Z element containing nanoparticles contain an element with an atomic Z number higher than 40, preferably higher than 50, and wherein said nanoparticles have a mean hydrodynamic diameter of 20 nm or less, for example between 1 and 10 nm, preferably between 2 and 8 nm.
Resumen de: US2025120914A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Resumen de: CN120346182A
本发明属于生物医药技术领域,具体涉及一种新型锰基纳米颗粒及制备方法和在抗癌中的应用。本发明首先提供了一种新型锰基纳米颗粒,所述新型锰基纳米颗粒由带正电荷的内核和带负电荷的外壳通过静电吸附作用形成,所述内核为高锰酸钾和聚醚酰亚胺发生氧化还原反应得到,为氧化锰‑聚醚酰亚胺复合体;所述外壳为阴离子聚合物。本发明还进一步提供了所述新型锰基纳米颗粒的制备方法和载药用途。
Resumen de: CN120346311A
本发明公开了一种草鱼呼肠孤病毒Ⅱ型mRNA疫苗、其制备方法及应用,属于疫苗领域。其技术方案包括一种草鱼呼肠孤病毒Ⅱ型mRNA疫苗,包括:修饰后的mRNA链;修饰后的mRNA链序列包括:5’UTR序列、Kozak序列、草鱼免疫球蛋白μ重链信号肽编码序列、GCRV II外衣壳蛋白VP35编码序列、3个终止密码子、3’UTR序列和polyA核酸序列。本发明应用于增强鱼体抗GCRV病毒感染能力、降低死亡率,填补目前草鱼呼肠孤病毒Ⅱ型mRNA疫苗的空白。
Resumen de: CN120346184A
本发明涉及药物学技术领域,尤其涉及一种脂质纳米粒子及其制备方法和应用。所述脂质纳米粒子包括:纳米磷脂盘和IMB‑AL0912;所述纳米磷脂盘包括:肺黏液成分磷脂、负电磷脂、蛋黄卵磷脂和4F肽;以质量比计,4F肽和肺黏液成分磷脂的质量比为1:(5~10)。本发明针对多黏菌素类抗生素研究得到一种新的脂质纳米粒子,通过改进的纳米磷脂盘负载多黏菌素类抗生素IMB‑AL0912得到的脂质纳米粒子,具备显著降低LPS刺激造成的细胞损伤、炎症因子表达的效果,对于细菌感染和败血症有着显著较优的防治效果,同时毒性更低,具有更广的临床应用范围。
Resumen de: CN120349507A
本发明提供一种聚氨基酸高分子材料,其化学式如下式所示:#imgabs0#,R1为亲水氨基酸重复片段或亲水与疏水氨基酸重复片段的组合;R2为连接子,用于连接亲水基团和疏水基团;R3为过渡子,用于加固疏水基团的连接,防止取代反应的发生;式中的六元环选自苯环、环己烷、杂环己烷、环己烯、杂环己烯、吡啶或吡喃中的至少一种;n和m为自然数。本发明使用聚氨基酸高分子材料代替PEG脂质,可有效规避预存抗PEG抗体的影响,拥有良好的生物可降解性,有效提高纳米粒的物理分散稳定性,增加纳米粒在体内的长循环,可将传统脂质纳米粒的四组份减少为三组份配方,使所制备的脂质体及纳米晶制剂在一定时间内具有优秀稳定性,保留脂质体本身的载药优势。
Resumen de: CN117919199A
The invention provides application of blank lipid nanoparticles in preparation of in-vivo delivery products, and belongs to the technical field of biological medicines. The application of the blank lipid nanoparticles in preparation of the in-vivo delivery product comprises the step of mixing the blank lipid nanoparticles with a biological active substance in a solvent to obtain a composition based on the blank lipid nanoparticles, the blank lipid nanoparticles comprise ionizable lipid, phospholipid, cholesterol and polyethylene glycol conjugated lipid. The blank lipid nanoparticles are adopted, the dosage of biological active substances can be flexibly adjusted according to the requirements of a user, drug delivery can be conducted in various ways such as intravenous injection, intramuscular injection, intraperitoneal injection and subcutaneous injection, and the ideal delivery effect can be obtained.
Resumen de: CN117925729A
The invention provides a transfection reagent based on blank lipid nanoparticles as well as a preparation method and application of the transfection reagent, and belongs to the technical field of biological medicines. The transfection reagent based on the blank lipid nanoparticles comprises the following components: (1) the blank lipid nanoparticles; (2) a biologically active ingredient; the blank lipid nanoparticles comprise ionizable lipid, phospholipid, cholesterol and polyethylene glycol conjugated lipid. The preparation process of the blank lipid nanoparticles and the transfection reagent is simple, and the preparation can be completed without the help of equipment. The transfection reagent based on the blank lipid nanoparticles is prepared from the blank lipid nanoparticles and nucleic acid, the dosage can be flexibly adjusted according to the requirements of a user, the transfection effect is stable, various cells (such as 293T, Hela, HepG2, TWO3 and MCF7) can be transfected, the cytotoxicity is low, and the transfection effect is good.
Resumen de: CN120324368A
本发明公开了一种藤黄酸B靶向lncRNA GAS5纳米递送系统,属于药物制剂技术领域,包括藤黄酸B;固体脂质;液体脂质;表面活性剂;磷脂;靶向配体修饰的聚乙二醇脂质;其中所述靶向配体修饰的聚乙二醇脂质包括叶酸修饰的聚乙二醇脂质和CD44抗体修饰的聚乙二醇脂质。本发明提供的藤黄酸B靶向lncRNA GAS5纳米递送系统在增强胃癌靶向性、提高药物递送效率、抑制胃癌转移和延长存活期方面均显示出显著优势。
Resumen de: WO2024126809A1
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Resumen de: CN120324602A
本发明属于药物制备领域,具体涉及一种双特异性细胞膜纳米粒及其制备方法与应用,所述制备方法包括以下步骤:将原代CD4+T细胞采用TGF‑β和雷帕霉素体外诱导为调节性T细胞;使二硬脂酰基磷脂酰乙醇胺‑聚乙二醇‑活性酯与抗CD4抗原结合片段反应,得到DP‑aCD4;调节性T细胞预孵育游离aCD4后,与DP‑aCD4共孵育,得到aCD4‑调节性T细胞;aCD4‑调节性T细胞与抗原肽和免疫抑制剂混合,通过脂质体挤出仪制备得到双特异性细胞膜纳米粒AP‑IA@aCD4Tn。本发明所述双特异性细胞膜纳米粒体内给药后可以高效诱导抗原特异性调节性T细胞的产生,实现对类风湿关节炎精准且高效的治疗和预防。
Resumen de: CN120324374A
本发明公开了一种可视化RNA类核酸药物递送的脂质纳米颗粒及其制备方法,属于生物医药材料技术领域,本发明合成了具有近红外光学特性的可电离阳离子脂质分子,按照经典四组分,即可电离阳离子脂质分子、胆固醇、DMG‑PEG‑2000和DSPC之间的不同摩尔比制备乙醇相,再将上述乙醇相快速打入至含RNA的水相中,从而制备一系列RNA‑LNPs。最后,通过紫外‑可见光光谱仪、荧光光谱仪、纳米粒度分析仪、透射电镜、溶血率测定等综合性分析RNA‑LNPs的基本理化性能,并筛选出安全稳定递送RNA的最优LNPs,本发明设计合成的新型LNPs具有良好的稳定性和荧光成像能力,可实现可视化的细胞或动物水平示踪。
Resumen de: CN120324630A
本发明提供了一种靶向炎症性肺组织的载药聚电解质复合物及其制备方法和应用。所述复合物由聚阳离子电解质、聚阴离子电解质、抗炎药物和两亲性分子AMs通过静电相互作用自组装形成。靶向M1型巨噬细胞。其中,聚阴离子电解质(如聚唾液酸,PSA)通过与巨噬细胞表面受体Siglec‑1结合,实现精准药物递送。同时,引入两亲性分子(AMs)以增强纳米颗粒的稳定性和药物包封率。本发明的聚电解质复合物能显著提高药物在炎症肺组织中的局部释放效率,有效减轻肺部炎症反应,具有广阔的临床应用前景。
Resumen de: CN120324371A
本发明涉及一种放射性碘标记的载药细菌外膜囊泡、制备方法及应用,属于生物医药技术领域。本发明通过表达富酪蛋白的减毒鼠伤寒沙门氏菌VNP20009分泌细菌外膜囊泡,利用超声法负载抗肿瘤药物,并结合氧化剂介导的放射性碘标记技术,构建具有肿瘤靶向性的经放射性碘标记的载药细菌外膜囊泡,并通过聚乙二醇修饰对其性能进行优化,载药质量比可控,放射性标记率高,体外稳定性好,体内安全性好。该载药细菌外膜囊泡可同时实现SPECT/PET显像及靶向治疗,适用于脑胶质瘤、结肠癌等实体瘤,兼具药物递送、免疫激活与放射诊断功能,具有良好的应用前景,为肿瘤的诊断与治疗提供了新工具。
Resumen de: CN120324327A
本发明提供了一种治疗口腔溃疡的水凝胶微针贴片及制备方法,属于生物医学工程技术领域。解决了口腔溃疡传统给药过程中药物难以在病灶处长时间滞留,易受唾液冲刷以及与舌和颊运动影响的技术问题。其技术方案为:包括以下步骤:1)设计并制备微针贴片模具;2)合成载药聚多巴胺纳米粒子;3)微针贴片的制备;4)微针贴片的性能评价。本发明的有益效果为:载药纳米粒子与水凝胶微针阵列的结合一方面可以通过药物缓释降低用药量的效果;另一方面有效地克服了药物不稳定性高、靶向性低、生物利用度差,阻碍治疗效果的问题,其可广泛应用于药物缓释、伤口愈合、组织工程等领域。
Nº publicación: CN120324377A 18/07/2025
Solicitante:
厦门大学
Resumen de: CN120324377A
本发明提供一种乙酰牛磺酸镁纳米眼药的制备方法,包括以下步骤:S1,制备乙酰牛磺酸镁纯药纳米颗粒;S2,制备高表达转铁蛋白的细胞膜囊泡;S3,将乙酰牛磺酸镁纳米颗粒和高表达转铁蛋白的细胞膜囊泡充分混合后超声,即得乙酰牛磺酸镁纳米眼药。本发明制备的高表达转铁蛋白的细胞膜囊泡装载的乙酰牛磺酸镁纳米眼药具有较高的药物浓度,并且具有长时间的药物稳定性。